Skip to main content
Erschienen in: CME 12/2014

29.12.2014 | CME Fortbildung

Die chronisch-obstruktive Lungenerkrankung (COPD)

Aktuelle Konzepte und neue Therapieoptionen

verfasst von: A. Klemmer, T. Greulich, A. R. Koczulla, C. F. Vogelmeier

Erschienen in: CME | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die chronisch-obstruktive Lungenerkrankung (COPD) ist eine sehr häufige chronische Erkrankung mit steigender Prävalenz. Eine Exposition gegenüber inhalativen Noxen, v. a. Tabakrauch, führt zu einer chronischen Entzündungsreaktion in den Atemwegen, begleitet von einer nicht voll reversiblen obstruktiven Ventilationsstörung. Die Zerstörung von Lungengewebe und damit eine Einschränkung des Gasaustauschs können folgen. Parallel wird eine Reihe von Komorbiditäten beobachtet. Die überarbeitete COPD-Klassifizierung berücksichtigt neben der Lungenfunktion auch Symptome und die anamnestische Häufigkeit von Exazerbationen. Kürzlich wurden mehrere neue lang wirkende Bronchodilatatoren für die Behandlung der COPD zugelassen. Kombinationspräparate, bestehend aus lang wirkenden β2-Sympathomimetika und Anticholinergika, sowie eine neue Kombination aus einem inhalierbaren Steroid und einem lang wirkenden β2-Mimetikum werden folgen. Auch der Rauchentwöhnung kommt eine entscheidende Bedeutung zu.
Literatur
[1]
Zurück zum Zitat Hogg JC, Chu F, Utokaparch S et al (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350:2645–2653PubMedCrossRef Hogg JC, Chu F, Utokaparch S et al (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350:2645–2653PubMedCrossRef
[2]
Zurück zum Zitat Lamprecht B, McBurnie MA, Vollmer WM et al (2011) COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 139:752–763PubMedCentralPubMedCrossRef Lamprecht B, McBurnie MA, Vollmer WM et al (2011) COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 139:752–763PubMedCentralPubMedCrossRef
[3]
[4]
Zurück zum Zitat Buist AS, McBurnie MA, Vollmer WM et al (2007) International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 370:741–750PubMedCrossRef Buist AS, McBurnie MA, Vollmer WM et al (2007) International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 370:741–750PubMedCrossRef
[6]
Zurück zum Zitat Hurst JR, Vestbo J, Anzueto A et al (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363:1128–1138PubMedCrossRef Hurst JR, Vestbo J, Anzueto A et al (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363:1128–1138PubMedCrossRef
[7]
Zurück zum Zitat Dodd JW, Hogg L, Nolan J et al (2011) The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax 66:425–429PubMedCrossRef Dodd JW, Hogg L, Nolan J et al (2011) The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax 66:425–429PubMedCrossRef
[8]
Zurück zum Zitat Mentz RJ, Wojdyla D, Fiuzat M et al (2013) Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol 111:582–587PubMedCrossRef Mentz RJ, Wojdyla D, Fiuzat M et al (2013) Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol 111:582–587PubMedCrossRef
[9]
Zurück zum Zitat Fagerstrom K, Russ C, Yu CR et al (2012) The Fagerstrom Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data. Nicotine Tob Res 14:1467–1473PubMedCrossRef Fagerstrom K, Russ C, Yu CR et al (2012) The Fagerstrom Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data. Nicotine Tob Res 14:1467–1473PubMedCrossRef
[10]
Zurück zum Zitat Anderson JE, Jorenby DE, Scott WJ, Fiore MC (2002) Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest 121:932–941PubMedCrossRef Anderson JE, Jorenby DE, Scott WJ, Fiore MC (2002) Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest 121:932–941PubMedCrossRef
[11]
Zurück zum Zitat Jorenby DE, Leischow SJ, Nides MA et al (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685–691PubMedCrossRef Jorenby DE, Leischow SJ, Nides MA et al (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685–691PubMedCrossRef
[12]
Zurück zum Zitat Tashkin DP, Rennard S, Hays JT et al (2011) Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 139:591–599PubMedCrossRef Tashkin DP, Rennard S, Hays JT et al (2011) Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 139:591–599PubMedCrossRef
[13]
Zurück zum Zitat Bullen C, Howe C, Laugesen M et al (2013) Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 382:1629–1637PubMedCrossRef Bullen C, Howe C, Laugesen M et al (2013) Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 382:1629–1637PubMedCrossRef
[14]
Zurück zum Zitat Magnussen H, Waschki B, Watz H (2009) Measurement of physical activity in patients with chronic obstructive pulmonary disease. Med Klin (Munich) 104:303–308CrossRef Magnussen H, Waschki B, Watz H (2009) Measurement of physical activity in patients with chronic obstructive pulmonary disease. Med Klin (Munich) 104:303–308CrossRef
[15]
Zurück zum Zitat Lacasse Y, Goldstein R, Lasserson TJ, Martin S (2006) Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev:CD003793 Lacasse Y, Goldstein R, Lasserson TJ, Martin S (2006) Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev:CD003793
[16]
Zurück zum Zitat Gloeckl R, Heinzelmann I, Baeuerle S et al (2012) Effects of whole body vibration in patients with chronic obstructive pulmonary disease — a randomized controlled trial. Respir Med 106:75–83PubMedCrossRef Gloeckl R, Heinzelmann I, Baeuerle S et al (2012) Effects of whole body vibration in patients with chronic obstructive pulmonary disease — a randomized controlled trial. Respir Med 106:75–83PubMedCrossRef
[17]
Zurück zum Zitat Poole PJ, Chacko E, Wood-Baker RW, Cates CJ (2006) Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev:CD002733 Poole PJ, Chacko E, Wood-Baker RW, Cates CJ (2006) Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev:CD002733
[18]
Zurück zum Zitat Pletz MW (2011) Pneumococcal vaccine: protection of adults and reduction of antibiotic resistence by vaccination of children with a conjugated vaccine. Med Monatsschr Pharm 34:201–205PubMed Pletz MW (2011) Pneumococcal vaccine: protection of adults and reduction of antibiotic resistence by vaccination of children with a conjugated vaccine. Med Monatsschr Pharm 34:201–205PubMed
[19]
Zurück zum Zitat Guevara M, Barricarte A, Gil-Setas A et al (2009) Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect 15:1013–1019PubMedCrossRef Guevara M, Barricarte A, Gil-Setas A et al (2009) Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect 15:1013–1019PubMedCrossRef
[20]
Zurück zum Zitat Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Aktualisierte Fassung Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Aktualisierte Fassung
[21]
Zurück zum Zitat Cazzola M, Santangelo G, Piccolo A et al (1994) Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 7:103–107PubMedCrossRef Cazzola M, Santangelo G, Piccolo A et al (1994) Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 7:103–107PubMedCrossRef
[22]
Zurück zum Zitat Kornmann O, Dahl R, Centanni S et al (2011) Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 37:273–279PubMedCrossRef Kornmann O, Dahl R, Centanni S et al (2011) Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 37:273–279PubMedCrossRef
[23]
Zurück zum Zitat Martinez FJ, Boscia J, Feldman G et al (2013) Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med 107:550–559PubMedCrossRef Martinez FJ, Boscia J, Feldman G et al (2013) Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med 107:550–559PubMedCrossRef
[24]
Zurück zum Zitat Vogelmeier C, Hederer B, Glaab T et al (2011) Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364:1093–1103PubMedCrossRef Vogelmeier C, Hederer B, Glaab T et al (2011) Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364:1093–1103PubMedCrossRef
[25]
Zurück zum Zitat Singh S, Loke YK, Enright PL, Furberg CD (2011) Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 342:d3215CrossRef Singh S, Loke YK, Enright PL, Furberg CD (2011) Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 342:d3215CrossRef
[26]
Zurück zum Zitat Wise RA, Anzueto A, Cotton D et al (2013) Tiotropium respimat inhaler and the risk of death in COPD. N Engl J Med 369:1491–1501PubMedCrossRef Wise RA, Anzueto A, Cotton D et al (2013) Tiotropium respimat inhaler and the risk of death in COPD. N Engl J Med 369:1491–1501PubMedCrossRef
[27]
Zurück zum Zitat Jones PW, Singh D, Bateman ED et al (2012) Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 40:830–836PubMedCrossRef Jones PW, Singh D, Bateman ED et al (2012) Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 40:830–836PubMedCrossRef
[28]
Zurück zum Zitat Donohue JF, Maleki-Yazdi MR, Kilbride S et al (2013) Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 107:1538–1546PubMedCrossRef Donohue JF, Maleki-Yazdi MR, Kilbride S et al (2013) Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 107:1538–1546PubMedCrossRef
[29]
Zurück zum Zitat Spencer S, Calverley PM, Burge PS, Jones PW (2004) Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 23:698–702PubMedCrossRef Spencer S, Calverley PM, Burge PS, Jones PW (2004) Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 23:698–702PubMedCrossRef
[30]
Zurück zum Zitat Janson C, Larsson K, Lisspers KH et al (2013) Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ 346:f3306CrossRef Janson C, Larsson K, Lisspers KH et al (2013) Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ 346:f3306CrossRef
[31]
Zurück zum Zitat Nannini LJ, Cates CJ, Lasserson TJ, Poole P (2007) Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev:CD003794 Nannini LJ, Cates CJ, Lasserson TJ, Poole P (2007) Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev:CD003794
[32]
Zurück zum Zitat Calverley P, Pauwels R, Vestbo J et al (2003) Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361:449–456PubMedCrossRef Calverley P, Pauwels R, Vestbo J et al (2003) Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361:449–456PubMedCrossRef
[33]
Zurück zum Zitat Szafranski W, Cukier A, Ramirez A et al (2003) Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21:74–81PubMedCrossRef Szafranski W, Cukier A, Ramirez A et al (2003) Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21:74–81PubMedCrossRef
[34]
Zurück zum Zitat Dransfield MT, Bourbeau J, Jones PW et al (2013) Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 1:210–223PubMedCrossRef Dransfield MT, Bourbeau J, Jones PW et al (2013) Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 1:210–223PubMedCrossRef
[35]
Zurück zum Zitat Wedzicha JA, Decramer M, Ficker JH et al (2013) Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, doubleblind, parallel-group study. Lancet Respir Med 1:199–209PubMedCrossRef Wedzicha JA, Decramer M, Ficker JH et al (2013) Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, doubleblind, parallel-group study. Lancet Respir Med 1:199–209PubMedCrossRef
[36]
Zurück zum Zitat D’Urzo A, Vogelmeier C (2012) Future of chronic obstructive disease management. Expert Rev Respir Med 6:285–299PubMedCrossRef D’Urzo A, Vogelmeier C (2012) Future of chronic obstructive disease management. Expert Rev Respir Med 6:285–299PubMedCrossRef
[37]
Zurück zum Zitat Wedzicha JA, Rabe KF, Martinez FJ et al (2013) Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest 143:1302–1311PubMedCrossRef Wedzicha JA, Rabe KF, Martinez FJ et al (2013) Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest 143:1302–1311PubMedCrossRef
[38]
Zurück zum Zitat Wouters EF, Bredenbroker D, Teichmann P et al (2012) Effect of the phosphodiesterase 4 inhibitor rofl umilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab 97:E1720–E1725PubMedCrossRef Wouters EF, Bredenbroker D, Teichmann P et al (2012) Effect of the phosphodiesterase 4 inhibitor rofl umilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab 97:E1720–E1725PubMedCrossRef
[39]
Zurück zum Zitat Poole P, Black PN, Cates CJ (2012) Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev:CD001287 Poole P, Black PN, Cates CJ (2012) Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev:CD001287
[40]
Zurück zum Zitat Zheng JP, Wen FQ, Bai CX et al (2013) High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study. COPD 10:164–171PubMedCrossRef Zheng JP, Wen FQ, Bai CX et al (2013) High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study. COPD 10:164–171PubMedCrossRef
[41]
Zurück zum Zitat Leuppi JD, Schuetz P, Bingisser R et al (2013) Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 309:2223–2231PubMedCrossRef Leuppi JD, Schuetz P, Bingisser R et al (2013) Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 309:2223–2231PubMedCrossRef
[42]
Zurück zum Zitat Llor C, Moragas A, Hernández S et al (2012) Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 186:716–723PubMedCrossRef Llor C, Moragas A, Hernández S et al (2012) Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 186:716–723PubMedCrossRef
[43]
Zurück zum Zitat Stockley RA, O’Brien C, Pye A, Hill SL (2009) Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. 2000. Chest 136(5 Suppl):e30 Stockley RA, O’Brien C, Pye A, Hill SL (2009) Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. 2000. Chest 136(5 Suppl):e30
[44]
Zurück zum Zitat Stolz D, Christ-Crain M, Bingisser R et al (2007) Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitoninguidance with standard therapy. Chest 131:9–19PubMedCrossRef Stolz D, Christ-Crain M, Bingisser R et al (2007) Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitoninguidance with standard therapy. Chest 131:9–19PubMedCrossRef
[45]
Zurück zum Zitat Sethi S, Murphy TF (2008) Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 359:2355–2365PubMedCrossRef Sethi S, Murphy TF (2008) Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 359:2355–2365PubMedCrossRef
Metadaten
Titel
Die chronisch-obstruktive Lungenerkrankung (COPD)
Aktuelle Konzepte und neue Therapieoptionen
verfasst von
A. Klemmer
T. Greulich
A. R. Koczulla
C. F. Vogelmeier
Publikationsdatum
29.12.2014
Verlag
Springer-Verlag
Erschienen in
CME / Ausgabe 12/2014
Print ISSN: 1614-371X
Elektronische ISSN: 1614-3744
DOI
https://doi.org/10.1007/s11298-014-1367-1

Weitere Artikel der Ausgabe 12/2014

CME 12/2014 Zur Ausgabe

Therapie aktuell

Infektiologie-Forschung

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.